Clinical Trial

Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with different immunization schedules (5-dose schedule group, two simple 4-dose schedule groups, and 2-1-1 schedule group) to evaluate the immunogenicity and safety of the vaccine.
Trial Details
NCT Number NCT07028801
Lead Sponsor Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Conditions Rabies
Enrollment 3,000 participants
Start Date 2025-07-31
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-19